Tenecteplase (TNKase): Nursing Drug Guide, STEMI Bolus Safety & NCLEX Review
Current TNKase labeling includes acute ischemic stroke (AIS) in adults and STEMI mortality reduction—both use a single IV bolus over 5 seconds, but dosing tables differ (AIS maximum 25 mg; STEMI 30–50 mg). This page emphasizes STEMI nursing safety and NCLEX practice; never apply STEMI weight-tier doses to AIS.
TNKase can cause serious internal and external bleeding, including intracranial hemorrhage. For STEMI (this page’s NCLEX focus), dosing is a single IV bolus over 5 seconds using STEMI weight tiers (30–50 mg). AIS uses a different table (15–25 mg maximum). Before any bolus, confirm indication, verify the correct tier for that indication, avoid intramuscular injections and unnecessary punctures, and reconcile concurrent antithrombotics. ASSENT-2 STEMI data reported intracranial hemorrhage in 0.9% and 30-day mortality of 6.2% with tenecteplase.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Before pushing TNKase for STEMI, confirm the indication on the order, verify the STEMI mg tier from current body weight (not AIS dosing), and protect the patient from avoidable puncture bleeding while adjunctive antithrombotic therapy is coordinated and monitored.
Most common brand names
TNKase is the marketed tenecteplase product in the reviewed U.S. prescribing information. Nursing checks focus on selecting the correct vial strength and reconstitution volume before dose withdrawal.
Tenecteplase is distinct from alteplase; they are not mg-for-mg substitutes and have different administration workflows. Verify the vial label reads TNKase before reconstitution.
Why we give it — Indications
Current TNKase prescribing information includes use for acute ischemic stroke (AIS) in adults and to reduce mortality in acute STEMI. Both routes use a single IV bolus over 5 seconds, but dosing differs by indication—AIS weight tiers run 15–25 mg (maximum 25 mg); STEMI tiers run 30–50 mg (maximum 50 mg). This page focuses on STEMI nursing safety and NCLEX practice unless otherwise stated; stroke pathways require the AIS table and blood-pressure control per labeling.
| Use | Detail |
|---|---|
| Acute ischemic stroke (AIS) | Adults with AIS: initiate as soon as possible and within 3 hours of stroke symptom onset; weight-tier bolus 15–25 mg (max 25 mg); frequently monitor and control blood pressure during and after administration per labeling. |
| Acute STEMI | Reduce mortality in adults with STEMI: single IV bolus thrombolytic with recommended adjunctive antithrombotic therapy; weight-tier doses 30–50 mg (max 50 mg). |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Tenecteplase is a fibrin-specific plasminogen activator that promotes fibrinolysis at the thrombus site. As with other thrombolytics, clinical benefit is paired with bleeding liability, so nursing surveillance for intracranial and non-compressible hemorrhage is continuous from bolus through post-dose observation.
Dosing overview
Do not interchange AIS and STEMI tables. Both indications use a single IV bolus over 5 seconds; verify the order indication before selecting mg tier.
STEMI weight-tier dosing (this page’s NCLEX focus)
| Body weight (STEMI) | TNKase dose |
|---|---|
| <60 kg | 30 mg |
| 60 to <70 kg | 35 mg |
| 70 to <80 kg | 40 mg |
| 80 to <90 kg | 45 mg |
| ≥90 kg | 50 mg (maximum STEMI dose) |
On a small screen, swipe or scroll sideways to see the full table.
AIS weight-tier dosing (reference only—not used in STEMI NCLEX items below)
| Body weight (AIS) | TNKase dose |
|---|---|
| <60 kg | 15 mg |
| 60 to <70 kg | 17.5 mg |
| 70 to <80 kg | 20 mg |
| 80 to <90 kg | 22.5 mg |
| ≥90 kg | 25 mg (maximum AIS dose) |
On a small screen, swipe or scroll sideways to see the full table.
Missed dose: Not specified in the reviewed prescribing information.
Renal and hepatic dosing adjustments: Not specified in the reviewed prescribing information.
STEMI vs AIS dosing: why nurses must never transfer one table to the other
A 70 kg patient receives 40 mg for STEMI but only 20 mg for AIS. Pulling a 50 mg syringe prepared for STEMI into a stroke pathway—or using AIS tiers during a heart-attack code—are high-risk errors that can cause bleeding or subtherapeutic lysis. Confirm indication on the order, the pathway checklist, and the printed weight-tier card before the 5-second bolus.
Before you give it — Safety check
Pretreatment checks
- Confirm STEMI diagnosis and symptom timeline with provider protocol before bolus preparation
- Verify body weight and correct weight-tier dose, then perform independent double-check under high-alert medication administration standards
- Review contraindications, including active internal bleeding and history of cerebrovascular events where listed
- Review baseline coagulation and antithrombotic plan, including adjunctive heparin, and reconcile prior therapies via medication reconciliation
Contraindications
- Active internal bleeding
- History of cerebrovascular accident
- Intracranial or intraspinal surgery or trauma within 2 months
- Intracranial neoplasm, arteriovenous malformation, or aneurysm
- Known bleeding diathesis
- Severe uncontrolled hypertension
Important interactions and co-therapy
| Drug / class | Effect | Nursing action |
|---|---|---|
| Aspirin | Used as adjunctive antithrombotic therapy but increases bleeding potential | Confirm intentional co-therapy and monitor for mucosal, GI, and access-site bleeding |
| Unfractionated heparin | Recommended adjunctive antithrombotic support in STEMI pathways | Check bolus/timing and trend coagulation parameters such as aPTT per protocol |
| Other anticoagulants / antiplatelets | Additive bleeding risk | Clarify sequence and necessity with prescriber/pharmacist before administration |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Route: Intravenous bolus only. Tenecteplase for STEMI is administered as a single bolus over 5 seconds.
- Use dedicated IV access when feasible; verify patency before bolus push
- Avoid intramuscular injections and minimize nonessential punctures after thrombolytic administration
- Coordinate frequent hemodynamic assessment using standardized blood pressure measurement technique
- Monitor closely for hypersensitivity including anaphylaxis, although serious reactions are uncommon
Expected therapeutic response
- Clinical reperfusion signs and improved ischemic symptom profile may occur after timely STEMI thrombolysis
- Reduction in persistent ischemic chest pain may be seen with successful reperfusion
- No severe bleeding or neurological deterioration during post-dose observation
Red flags — Stop and act
After TNKase bolus, any evidence of major bleeding or neurological decline requires immediate escalation.
- Sudden severe headache, confusion, new unilateral weakness, or drop in consciousness suggesting intracranial hemorrhage
- Persistent hypotension, tachycardia, or rapidly falling hemoglobin with possible occult internal bleed
- Uncontrolled access-site bleeding or expanding hematoma at puncture locations
- Any severe allergic-type respiratory or hemodynamic instability after bolus
Adverse effects
| Adverse effect | Label data | Nursing response |
|---|---|---|
| Bleeding | Most common adverse reaction per labeling; includes intracranial hemorrhage and fatal bleeding | Discontinue concomitant heparin or antiplatelet agents for serious uncontrolled bleeding; apply pressure ≥30 minutes to compressible sites |
| Intracranial hemorrhage (ASSENT-2) | 0.9% with tenecteplase versus 0.9% with accelerated alteplase at 30 days | Urgent neurologic evaluation and hemorrhage protocol; discontinue antithrombotics per team orders |
| Hypersensitivity | Most common adverse reactions include hypersensitivity (urticaria, anaphylaxis, angioedema, rash per labeling) | Monitor during and several hours after bolus; antihistamines and corticosteroids per severity |
On a small screen, swipe or scroll sideways to see the full table.
Overdose, toxicity, and antidote
Tenecteplase overdose is expected to increase bleeding risk. A routine specific antidote is not provided in the reviewed prescribing information.
- Stop further pro-bleeding exposures and activate institutional major hemorrhage pathway
- Coordinate urgent multidisciplinary management (cardiology, pharmacy, critical care, transfusion services)
- Routine antidote: Not specified in the reviewed prescribing information
Look-alike / sound-alike and error prevention
- Tenecteplase (TNKase) versus alteplase—different weight-tier bolus doses, reconstitution volumes, and administration times; verify drug name on the STEMI cart
- Weight-tier confusion (30/35/40/45/50 mg) is a high-risk error source during STEMI urgency
- Differentiate thrombolytic bolus orders from anticoagulant boluses on rapid order sets
- Use independent read-back for drug name, tier, total mg, and 5-second administration instruction
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Dose tier selection | Use current measured weight and verify the exact tier before drawing up tenecteplase. |
| Bolus timing | Administer as a single IV bolus over 5 seconds; do not convert into a prolonged infusion. |
| Puncture safety | Avoid IM injections and unnecessary arterial/venous punctures after dosing to reduce bleeding complications. |
| Post-dose vigilance | Trend neuro status and bleeding signs in frequent early reassessment windows. |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Clinical concern |
|---|---|
| Patients with prior cerebrovascular disease | Higher concern for intracranial bleeding when thrombolysis is given; confirm eligibility criteria closely. |
| Severe hypertension | Uncontrolled blood pressure increases hemorrhage risk during thrombolysis. |
| Recent surgery/trauma/puncture | Non-compressible bleeding sites can become life-threatening after TNKase. |
| Older adults (≥65 years) | ASSENT-2 reported higher 30-day mortality, stroke, intracranial hemorrhage, and major bleeds requiring transfusion or hemodynamic complications versus younger patients. |
| Pregnancy | STEMI is a medical emergency that can be fatal if untreated. Published data on related thrombolytics in pregnancy have not identified increased major birth defects; life-sustaining therapy should not be withheld because of fetal concerns per labeling. |
| Lactation | No data on tenecteplase in human or animal milk, effects on the breastfed infant, or milk production. Balance breastfeeding benefits against maternal clinical need and potential infant exposure. |
| Pediatrics | Safety and effectiveness not established in pediatric patients per labeling. |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Neurological status and any new focal deficit after administration
- Serial vital signs, access-site bleeding, and hemodynamic stability
- Coagulation and adjunctive anticoagulant targets per local STEMI protocol
- Ongoing symptom response, including recurrence of ischemic pain or perfusion compromise
Document
- Verified weight, selected tier, total mg administered, and exact administration time
- Statement that bolus was delivered over 5 seconds with independent double-check completed
- Adjunctive antithrombotic timing and immediate post-dose reassessment findings
Patient teaching
- Report any sudden headache, neurologic change, bleeding from gums/urine/stool, or recurrent severe pain immediately
- Avoid trauma and unnecessary injections after treatment while bleeding risk remains elevated
- Tell all clinicians about recent thrombolytic treatment before new procedures or medications
- Do not self-start OTC antithrombotic medications unless specifically directed by the care team
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- Any labeled contraindication is present or current bleeding concern is unresolved
- Weight-tier dose does not match verified current weight (30 mg to 50 mg table mismatch)
- Order does not specify single IV bolus over 5 seconds for STEMI pathway
- High-risk puncture/IM procedure is pending without coordinated risk plan
- Adjunctive antithrombotic plan is unclear or conflicting at administration time
Hold parameters can vary by local reperfusion pathway; follow prescriber orders and institutional protocol.
Clinical practice integration and workflow
Tenecteplase errors are usually dose-tier or workflow errors: wrong weight class, delayed bolus handling, avoidable puncture bleeding, or poor antithrombotic sequencing. Build a repeatable bedside safety huddle before every TNKase push.
1. Check-before-you-give protocol
- Confirm STEMI indication and signed thrombolytic order pathway
- Verify measured weight and exact dose tier from the label table
- Perform independent second check for drug, dose, route, and 5-second bolus instruction
- Confirm readiness for bleeding escalation and post-dose monitoring cadence
2. High-alert and safety badge
High-alert thrombolytic — tiered bolus + hemorrhage surveillanceTreat TNKase as high-alert with mandatory double-check, puncture minimization, and immediate escalation pathways for neurologic or bleeding deterioration.
3. Clinical workflow: hold and question rules
- Question dose immediately if weight or tier appears inconsistent with charted value
- Pause for unresolved bleeding risk conflicts before bolus administration
- Escalate fast for any new neurologic symptom after treatment, even if access-site bleeding looks minor
4. Critical teach-back questions
- “What bleeding or neurologic symptoms should be reported immediately?” (Patient/family should name at least two emergency cues.)
- “Why are we limiting unnecessary injections and punctures now?” (To lower post-thrombolytic bleeding risk.)
5. Care coordination
Pharmacist: Confirms dose-tier accuracy, reconstitution details, and antithrombotic sequencing.
Cardiology/critical care team: Directs reperfusion decisions, bleeding escalation, and post-thrombolysis reassessment pathway.
🧠 Quick mental checklist
- Is this confirmed STEMI and is TNKase appropriate right now?
- Does verified weight map to the exact 30/35/40/45/50 mg tier?
- Is the administration order clearly a single IV bolus over 5 seconds?
- Have IM injections and nonessential punctures been deferred?
- Is adjunctive antithrombotic monitoring and escalation plan active?
Tenecteplase NCLEX practice questions
Rehearse NCLEX-style clinical judgment practice for tenecteplase using a tabbed STEMI-only case (MAR, labs, vitals, nursing notes)—weight tiers are 30–50 mg, not AIS dosing (15–25 mg). Complete priority action, cue-recognition SATA, trend SATA, matrix urgency sorting, hold-rule decision, and cloze documentation on the required 5-second bolus.
Select a tab to view MAR, labs, vitals, and nursing note details for this case.
- Tenecteplase ordered now: single IV bolus for STEMI
- Current weight documented: 84 kg
- Aspirin chewed per protocol; heparin infusion order active after bolus
- No IM medications ordered in this administration window
- Hemoglobin 13.6 g/dL
- Platelets 228 x10^9/L
- Baseline aPTT 31 sec before heparin initiation
- Coagulation trend pending after adjunctive anticoagulation starts
- Arrival: BP 162/96, HR 108, RR 22, SpO2 95% room air
- Current: BP 156/92, HR 102, persistent chest discomfort but improving
- No focal neuro deficit on current bedside screen
- Nurse confirms STEMI diagnosis and TNKase order with cardiology
- Second nurse verified 84 kg tier corresponds to 45 mg tenecteplase
- Peripheral line patent; puncture-minimization plan reviewed with team
- Post-bolus neuro and bleeding checks scheduled at frequent intervals
Answer key & rationale
Frequently asked questions
What is the tenecteplase STEMI dose range?
For STEMI, TNKase labeling uses weight-tier bolus doses from 30 mg to 50 mg (maximum 50 mg) as a single IV bolus over 5 seconds. This differs from AIS dosing (15–25 mg maximum).
Is tenecteplase used for acute ischemic stroke?
Yes. Current TNKase labeling includes AIS in adults with separate weight-tier dosing given as a single IV bolus over 5 seconds, initiated as soon as possible within 3 hours of symptom onset. Use the AIS table—not STEMI tiers—for stroke pathways.
How fast should TNKase be administered?
Tenecteplase is administered as a single intravenous bolus over 5 seconds.
Why do nurses avoid IM injections and extra punctures after tenecteplase?
Because thrombolytic therapy increases bleeding risk, puncture minimization reduces preventable hemorrhagic complications.
Is heparin used with tenecteplase in STEMI pathways?
Yes. Adjunctive antithrombotic therapy, including heparin, is described in STEMI treatment pathways and requires close bleeding/coagulation monitoring.
What should trigger a hold before giving tenecteplase?
Hold for any unresolved contraindication, active bleeding concern, or weight-tier mismatch between verified weight and prepared dose.
Is there a routine antidote for tenecteplase overdose?
Not specified in the reviewed prescribing information as a routine antidote.
References
-
U.S. National Library of Medicine. TNKase (tenecteplase) for injection — Full prescribing information (AIS and STEMI indications). DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e647640d-c395-4b4b-a0be-1162f9c21d84
-
U.S. Food and Drug Administration. TNKase (tenecteplase) prescribing information label PDF.https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/103909s5197lbl.pdf
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.